modelA10BK03

Diagram of A10BK03

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:Empagliflozin
ATC code:A10BK03
route:oral
compartments:2
dosage:25mg
volume of distribution:73.8L
clearance:10.6L/h
other parameters in model implementation

Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used primarily for the management of type 2 diabetes mellitus. It lowers blood glucose by increasing renal glucose excretion. Empagliflozin is approved and widely used in clinical practice, including for reduction of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Pharmacokinetics

Population pharmacokinetic model in healthy adult volunteers after oral administration; parameters apply to both male and female adults.

References

  1. Riggs, MM, et al., & Macha, S (2013). Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. Journal of clinical pharmacology 53(10) 1028–1038. DOI:10.1002/jcph.147 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23940010

  2. Mondick, J, et al., & Nock, V (2018). Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus. Journal of clinical pharmacology 58(5) 640–649. DOI:10.1002/jcph.1051 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29251772

  3. Munir, KM, & Davis, SN (2016). Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes. Clinical pharmacology : advances and applications 8 19–34. DOI:10.2147/CPAA.S77754 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27186083

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)